Difference between revisions of "Team:Evry"
Knakiballz (Talk | contribs) m |
Knakiballz (Talk | contribs) m |
||
| Line 16: | Line 16: | ||
<h1>Welcome!</h1> <!-- to our project homepage --> | <h1>Welcome!</h1> <!-- to our project homepage --> | ||
</div> | </div> | ||
| + | <section class="page-section"> | ||
<h2>Abstract</h2> | <h2>Abstract</h2> | ||
<p class="lead">Reshaping immunotherapy landscape.</p> | <p class="lead">Reshaping immunotherapy landscape.</p> | ||
<p class="text-justify">Cancer thrives by preventing the immune system from targeting tumor cells. While current immunotherapies use dendritic cells to activate T-cells towards specific tumor antigens, they remain expensive and of variable efficiency against tumor immunosuppressive environment. To address these issues, our team mainly focused on engineering a <em>S. cerevisiae</em> yeast immunotherapy that was ultimately tested <strong>in vivo</strong> on mice presenting melanoma.</p> | <p class="text-justify">Cancer thrives by preventing the immune system from targeting tumor cells. While current immunotherapies use dendritic cells to activate T-cells towards specific tumor antigens, they remain expensive and of variable efficiency against tumor immunosuppressive environment. To address these issues, our team mainly focused on engineering a <em>S. cerevisiae</em> yeast immunotherapy that was ultimately tested <strong>in vivo</strong> on mice presenting melanoma.</p> | ||
<p class="text-justify">Three complementary strategies were combined: First, in order to modulate the tumor environment, yeast secreting immune modulators, GM-CSF and IFNgamma, were encapsulated into alginate beads and injected in tumors. Secondly, to break the immune tolerance against cancer cells, T4 and T8 lymphocytes were elicited by a yeast antigen display system. Last, to deliver cytotoxic compounds solely in the tumor environment, a yeast hypoxia bio-sensor was designed. A side project consisted in engineering E. coli to drive MAIT lymphocytes against cancer cells instead of their original targets, parasitized cells.</p> | <p class="text-justify">Three complementary strategies were combined: First, in order to modulate the tumor environment, yeast secreting immune modulators, GM-CSF and IFNgamma, were encapsulated into alginate beads and injected in tumors. Secondly, to break the immune tolerance against cancer cells, T4 and T8 lymphocytes were elicited by a yeast antigen display system. Last, to deliver cytotoxic compounds solely in the tumor environment, a yeast hypoxia bio-sensor was designed. A side project consisted in engineering E. coli to drive MAIT lymphocytes against cancer cells instead of their original targets, parasitized cells.</p> | ||
| + | </section> | ||
<!--div id="img-div"><img src="https://static.igem.org/mediawiki/2015/8/8a/Shcema_immune_syst.jpg" class="img-rounded img-responsive"></img></div--> | <!--div id="img-div"><img src="https://static.igem.org/mediawiki/2015/8/8a/Shcema_immune_syst.jpg" class="img-rounded img-responsive"></img></div--> | ||
<!--p class="lead">Dendritic cells can orchestrate the immune response. By acting on them using engineered micro-organisms, | <!--p class="lead">Dendritic cells can orchestrate the immune response. By acting on them using engineered micro-organisms, | ||
Revision as of 20:40, 31 August 2015
Welcome!
Abstract
Reshaping immunotherapy landscape.
Cancer thrives by preventing the immune system from targeting tumor cells. While current immunotherapies use dendritic cells to activate T-cells towards specific tumor antigens, they remain expensive and of variable efficiency against tumor immunosuppressive environment. To address these issues, our team mainly focused on engineering a S. cerevisiae yeast immunotherapy that was ultimately tested in vivo on mice presenting melanoma.
Three complementary strategies were combined: First, in order to modulate the tumor environment, yeast secreting immune modulators, GM-CSF and IFNgamma, were encapsulated into alginate beads and injected in tumors. Secondly, to break the immune tolerance against cancer cells, T4 and T8 lymphocytes were elicited by a yeast antigen display system. Last, to deliver cytotoxic compounds solely in the tumor environment, a yeast hypoxia bio-sensor was designed. A side project consisted in engineering E. coli to drive MAIT lymphocytes against cancer cells instead of their original targets, parasitized cells.
To top